Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Alice I. Nichols"'
Publikováno v:
Clinical Pharmacology in Drug Development. 7:441-450
Desvenlafaxine exposure in Korean and US populations was compared using population pharmacokinetic (PK) analysis. Data from a single- and multiple-dose study of desvenlafaxine (50, 100, and 200 mg) in 30 healthy Korean subjects were added to a popula
Autor:
Alice I. Nichols, Lingfeng Yang, Karen A. Tourian, Robert L. Findling, Sara Ramaker, James Groark, Deborah Chiles
Publikováno v:
Journal of Child and Adolescent Psychopharmacology. 26:909-921
To investigate the safety and pharmacokinetic profile of ascending doses of desvenlafaxine in children and adolescents with major depressive disorder. Assessment of the effect of desvenlafaxine on depression symptoms was exploratory.The 8-week, open-
Autor:
Alice I. Nichols, Shannon Lubaczewski, Kyle Matschke, Tanya Ramey, Yali Liang, Gabriel Braley
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 52:830-841
Background Potential drugdrug interactions are a concern for patients taking tamoxifen. Objective This study was designed to determine the effect of coadministering desvenlafaxine on tamoxifen pharmacokinetics. Materials and methods This open-label,
Autor:
Kasia Lobello, Rana Fayyad, Kristen Focht, Gina Buckley, Cecelia P. Kane, Sheldon H. Preskorn, Christine J. Guico-Pabia, Alice I. Nichols
Publikováno v:
The Journal of Clinical Psychiatry. 74:614-621
OBJECTIVE Determine the point prevalence of phenoconversion to cytochrome P450 2D6 (CYP2D6) poor metabolizer status in clinical practice. METHOD This multicenter, open-label, single-visit naturalistic study was conducted from October 2008 to July 200
Autor:
Kasia Lobello, Sheldon H. Preskorn, Philip T. Ninan, Albena Patroneva, Jeffrey Paul, Christine J. Guico-Pabia, Qin Jiang, Alice I. Nichols
Publikováno v:
The Journal of Clinical Psychiatry. 71:1482-1487
Introduction Venlafaxine, a serotonin-norepinephrine reuptake inhibitor antidepressant, is metabolized primarily by the cytochrome P450 2D6 enzyme into O-desmethylvenlafaxine (ODV). The ODV/venlafaxine ratio can be used to distinguish between extensi
Publikováno v:
Journal of Clinical Psychopharmacology. 29:383-386
One of the major enzymes of the cytochrome P450 drug-metabolizing system, CYP2D6, shows a high degree of genetic polymorphism and variability in activity. Based on the degree of CYP2D6 activity, individuals can be broadly classified as poor metaboliz
Autor:
Heather Silman, Jennifer A. Isler, Albena Patroneva, Michael E. Burczynski, Qin Jiang, Sheldon H. Preskorn, Alice I. Nichols, Saeeduddin Ahmed, Jeffrey Paul
Publikováno v:
Journal of Clinical Psychopharmacology. 29:39-43
Background: The goal of this study was to evaluate the impact of cytochrome P450 2D6 extensive metabolizer (EM) or poor metabolizer (PM) status on the pharmacokinetics of single doses of venlafaxine extended release (ER) and desvenlafaxine (administe
Autor:
Eileen C Helzner, Sheldon H. Preskorn, Christine J Guico-Pabia, Jeffrey Paul, Alice I. Nichols, Albena Patroneva
Publikováno v:
Journal of Psychiatric Practice. 14:368-378
BACKGROUND The cytochrome P450 2D6 (CYP2D6) enzyme is responsible for metabolizing approximately 25% of pharmaceutical agents. Individuals with impaired CYP2D6 metabolism and those concomitantly receiving agents that inhibit CYP2D6 can have variation
Autor:
Ron Pedersen, Penny Fatato, Christine J Guico-Pabia, Alice I. Nichols, Albena Patroneva, Jeffrey Paul, Jennifer A. Isler, Qin Jiang, Michael E. Burczynski, Sandra M. Connolly
Publikováno v:
Drug Metabolism and Disposition. 36:2484-2491
A number of antidepressants inhibit the activity of the cytochrome P450 2D6 enzyme system, which can lead to drug-drug interactions. Based on its metabolic profile, desvenlafaxine, administered as desvenlafaxine succinate, a new serotonin-norepinephr
Publikováno v:
The primary care companion for CNS disorders. 17(2)
The avoidance of adverse drug-drug interactions (DDIs) is a high priority in terms of both the US Food and Drug Administration (FDA) and the individual prescriber. With this perspective in mind, this article illustrates the process for assessing the